In a filing, BridgeBio Pharma Inc revealed its Director FRANK P. MCCORMICK acquired Company’s shares for reported $3.93 million on Sep 05 ’25. In the deal valued at $53.14 per share,74,000 shares were bought.
Then, Trimarchi Thomas sold 42,237 shares, generating $2,090,081 in total proceeds. Upon selling the shares at $49.48, the President and CFO now owns 421,081 shares.
Before that, Kumar Neil sold 26,156 shares. BridgeBio Pharma Inc shares valued at $1,276,927 were divested by the Chief Executive Officer at a price of $48.82 per share. As a result of the transaction, Kumar Neil now holds 223,090 shares, worth roughly $11.91 million.
A number of analysts have revised their coverage, including Truist’s analysts, who began to cover the stock in late July with a ‘”a Buy”‘ rating. Jefferies began covering BBIO with “Buy” recommendation on July 14, 2025. Oppenheimer revised its rating on July 09, 2025. It rated BBIO as “an Outperform” which previously was an “a Perform”.
Price Performance Review of BBIO
On Friday, BridgeBio Pharma Inc [NASDAQ:BBIO] saw its stock jump 2.99% to $53.38. Over the last five days, the stock has gained 1.54%. BridgeBio Pharma Inc shares have risen nearly 85.73% since the year began. Nevertheless, the stocks have risen 94.53% over the past one year. While a 52-week high of $52.85 was reached on 09/05/25, a 52-week low of $21.72 was recorded on 01/02/25.
Levels Of Support And Resistance For BBIO Stock
The 24-hour chart illustrates a support level at 51.93, which if violated will result in even more drops to 50.48. On the upside, there is a resistance level at 54.40. A further resistance level may holdings at 55.42.
How much short interest is there in BridgeBio Pharma Inc?
A steep rise in short interest was recorded in BridgeBio Pharma Inc stocks on 2025-08-15, growing by 1.01 million shares to a total of 20.49 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-15 was 19.48 million shares. There was a rise of 4.93%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 17, 2025 when Wolfe Research began covering the stock and recommended ‘”an Outperform”‘ rating along with a $49 price target.
